244 related articles for article (PubMed ID: 21386843)
1. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
[TBL] [Abstract][Full Text] [Related]
2. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.
Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F
Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.
Massard C; Borget I; Le Deley MC; Taylor M; Gomez-Roca C; Soria JC; Farace F
Eur J Cancer; 2012 Jun; 48(9):1354-62. PubMed ID: 22370181
[TBL] [Abstract][Full Text] [Related]
4. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
[TBL] [Abstract][Full Text] [Related]
5. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
6. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Gruenwald V; Beutel G; Schuch-Jantsch S; Reuter C; Ivanyi P; Ganser A; Haubitz M
BMC Cancer; 2010 Dec; 10():695. PubMed ID: 21194438
[TBL] [Abstract][Full Text] [Related]
7. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
Schmidt-Lucke C; Fichtlscherer S; Aicher A; Tschöpe C; Schultheiss HP; Zeiher AM; Dimmeler S
PLoS One; 2010 Nov; 5(11):e13790. PubMed ID: 21072182
[TBL] [Abstract][Full Text] [Related]
8. Regulation of circulating progenitor cells in left ventricular dysfunction.
Boilson BA; Larsen K; Harbuzariu A; Delacroix S; Korinek J; Froehlich H; Bailey KR; Scott CG; Shapiro BP; Boerrigter G; Chen HH; Redfield MM; Burnett JC; Simari RD
Circ Heart Fail; 2010 Sep; 3(5):635-42. PubMed ID: 20573992
[TBL] [Abstract][Full Text] [Related]
9. Concurrent hypermulticolor monitoring of CD31, CD34, CD45 and CD146 endothelial progenitor cell markers for acute myocardial infarction.
Shim Y; Nam MH; Hyuk SW; Yoon SY; Song JM
Anal Chim Acta; 2015 Jan; 853():501-507. PubMed ID: 25467496
[TBL] [Abstract][Full Text] [Related]
10. Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients.
Golab-Janowska M; Paczkowska E; Machalinski B; Kotlega D; Meller A; Safranow K; Wankowicz P; Nowacki P
Curr Neurovasc Res; 2019; 16(1):19-26. PubMed ID: 30706812
[TBL] [Abstract][Full Text] [Related]
11. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
[TBL] [Abstract][Full Text] [Related]
12. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
[TBL] [Abstract][Full Text] [Related]
13. Circulating hematopoietic and endothelial progenitor cells in newborn infants: effects of gestational age, postnatal age and clinical stress in the first 3 weeks of life.
Bui KC; Weems M; Biniwale M; George AA; Zielinska E; Azen CG; Durand M; Abdel-Azim H
Early Hum Dev; 2013 Jun; 89(6):411-8. PubMed ID: 23312395
[TBL] [Abstract][Full Text] [Related]
14. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
15. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors.
Karampinis I; Joas E; Dreyer A; Ronellenfitsch U; Jakob J; Hohenberger P; Nowak K
Eur J Surg Oncol; 2018 Apr; 44(4):496-501. PubMed ID: 29397265
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
18. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells.
Brunner S; Theiss HD; Murr A; Negele T; Franz WM
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1670-5. PubMed ID: 17911347
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
20. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
